Radiobiotherapy in Osteosarcoma: A State-Based Educational Framework for Strategy Selection and Trial Design

Area of Science:

• Oncology
• Radiation Oncology
• Translational Medicine

Background:

• Osteosarcoma is a complex cancer with plateauing survival rates despite multimodal therapy.
• Its genetic complexity, including structural variations and clonal evolution, limits precision oncology.
• Novel frameworks are needed to align treatment with evolving disease characteristics.

Purpose of the Study:

• To propose a state-based framework for integrating radiotherapy into osteosarcoma management.
• To guide clinical trial design by emphasizing dynamic disease variables over static staging.
• To explore radiotherapy's role as a biologic intervention beyond local control.

Main Methods:

• Narrative educational review synthesizing evidence from osteosarcoma biology, radiobiology, and translational oncology.
• Development of a state-based framework considering disease burden, progression tempo, systemic response, and local control feasibility.
• Integration of stereotactic body radiotherapy (SBRT/SABR) and spatially fractionated radiotherapy (SFRT) into the framework.

Main Results:

• Radiotherapy is presented as a local control modality and a biologic intervention affecting tumor microenvironment.
• Potential benefits include local eradication and immune modulation; limitations involve abscopal response rarity and systemic signaling risks.
• Dose, fractionation, and spatial distribution of radiotherapy influence its biologic effects.

Conclusions:

• The proposed framework supports state-stratified, biomarker-embedded clinical trials for osteosarcoma.
• Highlights novel endpoints like circulating tumor DNA dynamics and immune/myeloid signatures.
• Frames radiobiotherapy as an educational paradigm for hypothesis generation and learning-oriented trial designs.